Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia

Differentiation

Volumn 82, Issue 4-5, 2011, Pages 211-219

  Mehta, Vatsal ^a   Vezina, Chad M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

AHR; Androgen; BPH; Development; Prostate; Vasculature

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; DUTASTERIDE; ENDOCRINE DISRUPTOR; ESTRADIOL; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 10; FINASTERIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; TAMSULOSIN; TESTOSTERONE; WNT5A PROTEIN;

AGING; ANGIOGENESIS; BRANCHING MORPHOGENESIS; CANCER RISK; CHRONIC INFLAMMATION; ENVIRONMENTAL EXPOSURE; GENETIC TRANSCRIPTION; HEMATURIA; HUMAN; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; UROGENITAL SINUS;

ANIMALS; HUMANS; INFLAMMATION; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

RODENTIA;

EID: 80052966599     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2011.05.011     Document Type: Review

References (117)

1. Ackermann M.F., Gasiewicz T.A., Lamm K.R., Germolec D.R., Luster M.I. Selective inhibition of polymorphonuclear neutrophil activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1989, 101:470-480.
2. Akhtar F.Z., Garabrant D.H., Ketchum N.S., Michalek J.E. Cancer in US Air Force veterans of the Vietnam War. J. Occup. Environ. Med. 2004, 46:123-136.
3. Allgeier S.H., Lin T.M., Vezina C.M., Moore R.W., Fritz W.A., Chiu S.Y., Zhang C., Peterson R.E. WNT5A selectively inhibits mouse ventral prostate development. Dev. Biol. 2008, 324:10-17.
4. Allgeier S.H., Moore R.W., Lin T.-M., Vezina C.M., Peterson R.E. Androgenic regulation of ventral epithelial bud number and pattern in mouse urogenital sinus. Dev. Dyn. 2010, 239:373-385.
5. Andreasen E.A., Mathew L.K., Lohr C.V., Hasson R., Tanguay R.L. Aryl hydrocarbon receptor activation impairs extracellular matrix remodeling during zebra fish fin regeneration. Toxicol. Sci. 2007, 95:215-226.
6. Arima A., Kato H., Ise R., Ooshima Y., Inoue A., Muneoka A., Kamimura S., Fukusato T., Kubota S., Sumida H., Yasuda M. In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces disruption of glands of the prostate and fibrosis in rhesus monkeys. Reprod. Toxicol. 2010, 29:317-322.
7. Asgari S.A., Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int. J. Prev. Med. 2011, 2:28-31.
8. Ashton N. Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. Am. J. Ophthalmol. 1966, 62:412-435.
9. Begley L.A., Kasina S., MacDonald J., Macoska J.A. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008, 43:194-199.
10. Benson J.M., Shepherd D.M. Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. Toxicol. Sci. 2011, 120:68-78.
11. Bianchi-Frias D., Vakar-Lopez F., Coleman I.M., Plymate S.R., Reed M.J., Nelson P.S. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 2010, 5.
12. Burbach K.M., Poland A., Bradfield C.A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. USA 1992, 89:8185-8189.
13. Carnell D.M., Smith R.E., Daley F.M., Barber P.R., Hoskin P.J., Wilson G.D., Murray G.I., Everett S.A. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:500-509.
14. Carver L.A., LaPres J.J., Jain S., Dunham E.E., Bradfield C.A. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem. 1998, 273:33580-33587.
15. Chamie K., DeVere White R.W., Lee D., Ok J.H., Ellison L.M. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer 2008, 113:2464-2470.
16. Cox M.B., Miller C.A. Cooperation of heat shock protein 90 and p23 in aryl hydrocarbon receptor signaling. Cell Stress Chaperones 2004, 9:4-20.
17. Cunha G.R. The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat. Rec. 1973, 175:87-96.
18. Cunha G.R., Lung B. The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J. Exp. Zool. 1978, 205:181-193.
19. Deering R.E., Bigler S.A., Brown M., Brawer M.K. Microvascularity in benign prostatic hyperplasia. Prostate 1995, 26:111-115.
20. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43:309-334.
21. Dhooge W., van Larebeke N., Koppen G., Nelen V., Schoeters G., Vlietinck R., Kaufman J.M., Comhaire F., Flemish E., Health Study G. Serum dioxin-like activity is associated with reproductive parameters in young men from the general Flemish population. Environ. Health Perspect. 2006, 114:1670-1676.
22. Dong W., Teraoka H., Tsujimoto Y., Stegeman J.J., Hiraga T. Role of aryl hydrocarbon receptor in mesencephalic circulation failure and apoptosis in zebrafish embryos exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Sci. 2004, 77:109-116.
23. Donjacour A.A., Thomson A.A., Cunha G.R. FGF-10 plays an essential role in the growth of the fetal prostate. Dev. Biol. 2003, 261:39-54.
24. Emmons R.B., Duncan D., Estes P.A., Kiefel P., Mosher J.T., Sonnenfeld M., Ward M.P., Duncan I., Crews S.T. The spineless-aristapedia and tango bHLH-PAS proteins interact to control antennal and tarsal development in Drosophila. Development 1999, 126:3937-3945.
25. Endo F., Monsees T.K., Akaza H., Schill W.B., Pflieger-Bruss S. Effects of single non-ortho, mono-ortho, and di-ortho chlorinated biphenyls on cell functions and proliferation of the human prostatic carcinoma cell line, LNCaP. Reprod. Toxicol. 2003, 17:229-236.
26. Foley S.J., Bailey D.M. Microvessel density in prostatic hyperplasia. BJU Int. 2000, 85:70-73.
27. Franczak A., Nynca A., Valdez K.E., Mizinga K.M., Petroff B.K. Effects of acute and chronic exposure to the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin on the transition to reproductive senescence in female Sprague-Dawley rats. Biol. Reprod. 2006, 74:125-130.
28. Fritz W.A., Lin T.M., Cardiff R.D., Peterson R.E. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2007, 28:497-505.
29. Fritz W.A., Lin T.M., Moore R.W., Cooke P.S., Peterson R.E. In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on the prostate and its response to castration in senescent C57BL/6J mice. Toxicol. Sci. 2005, 86:387-395.
30. Fritz W.A., Lin T.M., Moore R.W., Cooke P.S., Peterson R.E. In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on the prostate and its response to castration in senescent C57BL/6J mice. Toxicol. Sci. 2005, 86:387-395.
31. Fritz, W.A., Lin, T.M., Peterson, R.E., 2008. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis.
32. Fritz W.A., Lin T.M., Safe S., Moore R.W., Peterson R.E. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem. Pharmacol. 2009, 77:1151-1160.
33. Fukuzawa N.H., Ohsako S., Wu Q., Sakaue M., Fujii-Kuriyama Y., Baba T., Tohyama C. Testicular cytochrome P450scc and LHR as possible targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the mouse. Mol. Cell. Endocrinol. 2004, 221:87-96.
34. Funatake C.J., Marshall N.B., Steppan L.B., Mourich D.V., Kerkvliet N.I. Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J. Immunol. 2005, 175:4184-4188.
35. Giri V.N., Cassidy A.E., Beebe-Dimmer J., Ellis L.R., Smith D.C., Bock C.H., Cooney K.A. Association between Agent Orange and prostate cancer: a pilot case-control study. Urology 2004, 63:757-760. discussion 760-751.
36. Gonzalez F.J., Fernandez-Salguero P., Ward J.M. The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. J. Toxicol. Sci. 1996, 21:273-277.
37. Gray L.E., Ostby J.S., Kelce W.R. A dose-response analysis of the reproductive effects of a single gestational dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male Long Evans Hooded rat offspring. Toxicol. Appl. Pharmacol. 1997, 146:11-20.
38. Gupta A., Ketchum N., Roehrborn C.G., Schecter A., Aragaki C.C., Michalek J.E. Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Environ. Health Perspect. 2006, 114:1649-1654.
39. Gupta A., Schecter A., Aragaki C.C., Roehrborn C.G. Dioxin exposure and benign prostatic hyperplasia. J. Occup. Environ. Med. 2006, 48:708-714.
40. Hahn M.E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact. 2002, 141:131-160.
41. Ho C.K., Nanda J., Chapman K.E., Habib F.K. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J. Endocrinol. 2008, 197:483-491.
42. Huang L., Pu Y., Hu W.Y., Birch L., Luccio-Camelo D., Yamaguchi T., Prins G.S. The role of Wnt5a in prostate gland development. Dev. Biol. 2009, 328:188-199.
43. Institute of Medicine (U.S.), 2007. Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides, and National Academies Press (U.S.). Veterans and Agent Orange: update 2006. National Academies Press, Washington, DC.
44. Ishimura R., Kawakami T., Ohsako S., Nohara K., Tohyama C. Suppressive effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on vascular remodeling that takes place in the normal labyrinth zone of rat placenta during late gestation. Toxicol. Sci. 2006, 91:265-274.
45. Ivnitski-Steele I.D., Walker M.K. Vascular endothelial growth factor rescues 2,3,7,8-tetrachlorodibenzo-p-dioxin inhibition of coronary vasculogenesis. Birth Defects Res. A Clin. Mol. Teratol. 2003, 67:496-503.
46. Jablonska O., Shi Z., Valdez K.E., Ting A.Y., Petroff B.K. Temporal and anatomical sensitivities to the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin leading to premature acyclicity with age in rats. Int. J. Androl. 2010, 33:405-412.
47. Jain S., Dolwick K.M., Schmidt J.V., Bradfield C.A. Potent transactivation domains of the Ah receptor and the Ah receptor nuclear translocator map to their carboxyl termini. J. Biol. Chem. 1994, 269:31518-31524.
48. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., Sone H. Comparative effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on MCF-7, RL95-2, and LNCaP cells: role of target steroid hormones in cellular responsiveness to CYP1A1 induction. Mol. Cell. Biol. Res. Commun. 2000, 4:174-180.
49. Kashani M., Steiner G., Haitel A., Schaufler K., Thalhammer T., Amann G., Kramer G., Marberger M., Scholler A. Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate. Prostate 1998, 37:98-108.
50. Kimura A., Naka T., Nakahama T., Chinen I., Masuda K., Nohara K., Fujii-Kuriyama Y., Kishimoto T. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 2009, 206:2027-2035.
51. Ko K., Moore R.W., Peterson R.E. Aryl hydrocarbon receptors in urogenital sinus mesenchyme mediate the inhibition of prostatic epithelial bud formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 2004, 196:149-155.
52. Ko K., Theobald H.M., Moore R.W., Peterson R.E. Evidence that inhibited prostatic epithelial bud formation in 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed C57BL/6J fetal mice is not due to interruption of androgen signaling in the urogenital sinus. Toxicol. Sci. 2004, 79:360-369.
53. Ko K., Theobald H.M., Peterson R.E. In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in the C57BL/6J mouse prostate: lobe-specific effects on branching morphogenesis. Toxicol. Sci. 2002, 70:227-237.
54. Kohnen P.W., Drach G.W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J. Urol. 1979, 121:755-760.
55. Kojima M., Watanabe H., Watanabe M., Okihara K., Naya Y., Ukimura O. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med. Biol. 1997, 23:1305-1309.
56. Kollara A., Brown T.J. Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. J. Steroid Biochem. Mol. Biol. 2010, 118:51-58.
57. Komura K., Hayashi S., Makino I., Poellinger L., Tanaka H. Aryl hydrocarbon receptor/dioxin receptor in human monocytes and macrophages. Mol. Cell. Biochem. 2001, 226:107-118.
58. Korenaga T., Fukusato T., Ohta M., Asaoka K., Murata N., Arima A., Kubota S. Long-term effects of subcutaneously injected 2,3,7,8-tetrachlorodibenzo-p-dioxin on the liver of rhesus monkeys. Chemosphere 2007, 67:S399-404.
59. Kramer G., Steiner G.E., Handisurya A., Stix U., Haitel A., Knerer B., Gessl A., Lee C., Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002, 52:43-58.
60. Lahvis G.P., Pyzalski R.W., Glover E., Pitot H.C., McElwee M.K., Bradfield C.A. The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. Mol. Pharmacol. 2005, 67:714-720.
61. Lasnitzki I., Mizuno T. Prostatic induction: interaction of epithelium and mesenchyme from normal wild-type mice and androgen-insensitive mice with testicular feminization. J. Endocrinol. 1980, 85:423-428.
62. Lawrence B.P., Leid M., Kerkvliet N.I. Distribution and behavior of the Ah receptor in murine T lymphocytes. Toxicol. Appl. Pharmacol. 1996, 138:275-284.
63. Lin T.-L., Hopkins W.J., Torrealba J.R., Briggs P.M., Roenneburg D.A., Fritz W., Lin J., Peterson R.E. Development of prostate dysplasia following transient prostatitis in C57Bl/6J mice: Lack of effect of aryl hydrocarbon receptor (AhR) genotype. American Association for Cancer Research 2007, American Association for Cancer Research, Los Angeles, CA.
64. Lin T.M., Ko K., Moore R.W., Simanainen U., Oberley T.D., Peterson R.E. Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice. Toxicol. Sci. 2002, 68:479-487.
65. Lin T.M., Rasmussen N.T., Moore R.W., Albrecht R.M., Peterson R.E. Region-specific inhibition of prostatic epithelial bud formation in the urogenital sinus of C57BL/6 mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Sci. 2003, 76:171-181.
66. Lin T.M., Rasmussen N.T., Moore R.W., Albrecht R.M., Peterson R.E. Region-specific inhibition of prostatic epithelial bud formation in the urogenital sinus of C57BL/6 mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Sci. 2003, 76:171-181.
67. Ma L., Wang H.Y. Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway. J. Biol. Chem. 2007, 282:28980-28990.
68. Mably T.A., Moore R.W., Peterson R.E. In utero and lactational exposure of male rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1. Effects on androgenic status. Toxicol. Appl. Pharmacol. 1992, 114:97-107.
69. Mathew L.K., Andreasen E.A., Tanguay R.L. Aryl hydrocarbon receptor activation inhibits regenerative growth. Mol. Pharmacol. 2006, 69:257-265.
70. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1997, 94:8104-8109.
71. McIntosh B.E., Hogenesch J.B., Bradfield C.A. Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu. Rev. Physiol. 2010, 72:625-645.
72. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest. Urol. 1978, 15:340-345.
73. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4:e115.
74. Mishra V.C., Allen D.J., Nicolaou C., Sharif H., Hudd C., Karim O.M., Motiwala H.G., Laniado M.E. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?. BJU Int. 2007, 100:327-331.
75. Mitchell K.A., Lockhart C.A., Huang G., Elferink C.J. Sustained aryl hydrocarbon receptor activity attenuates liver regeneration. Mol. Pharmacol. 2006, 70:163-170.
76. Mocarelli P., Gerthoux P.M., Patterson D.G., Milani S., Limonta G., Bertona M., Signorini S., Tramacere P., Colombo L., Crespi C., Brambilla P., Sarto C., Carreri V., Sampson E.J., Turner W.E., Needham L.L. Dioxin exposure, from infancy through puberty, produces endocrine disruption and affects human semen quality. Environ. Health Perspect. 2008, 116:70-77.
77. Morrow D., Qin C., Smith R., Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol. 2004, 88:27-36.
78. Murray G.I., Taylor V.E., McKay J.A., Weaver R.J., Ewen S.W., Melvin W.T., Burke M.D. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J. Pathol. 1995, 177:147-152.
79. Nakano K., Fukabori Y., Itoh N., Lu W., Kan M., McKeehan W.L., Yamanaka H. Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr. J. 1999, 46:405-413.
80. Needham L.L., Gerthoux P.M., Patterson D.G., Brambilla P., Turner W.E., Beretta C., Pirkle J.L., Colombo L., Sampson E.J., Tramacere P.L., Signorini S., Meazza L., Carreri V., Jackson R.J., Mocarelli P. Serum dioxin levels in Seveso, Italy, population in 1976. Teratogen. Carcinog. Mutagen. 1997, 17:225-240.
81. Nickel J.C., Roehrborn C.G., O'Leary M.P., Bostwick D.G., Somerville M.C., Rittmaster R.S. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 2008, 54:1379-1384.
82. O'Donnell E.F., Saili K.S., Koch D.C., Kopparapu P.R., Farrer D., Bisson W.H., Mathew L.K., Sengupta S., Kerkvliet N.I., Tanguay R.L., Kolluri S.K. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One 2010, 5.
83. Ohsako S., Miyabara Y., Nishimura N., Kurosawa S., Sakaue M., Ishimura R., Sato M., Takeda K., Aoki Y., Sone H., Tohyama C., Yonemoto J. Maternal exposure to a low dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppressed the development of reproductive organs of male rats: dose-dependent increase of mRNA levels of 5alpha-reductase type 2 in contrast to decrease of androgen receptor in the pubertal ventral prostate. Toxicol. Sci. 2001, 60:132-143.
84. Ohtake F., Baba A., Takada I., Okada M., Iwasaki K., Miki H., Takahashi S., Kouzmenko A., Nohara K., Chiba T., Fujii-Kuriyama Y., Kato S. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007, 446:562-566.
85. Ohtake F., Fujii-Kuriyama Y., Kato S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol. 2009, 77:474-484.
86. Okino S.T., Whitlock J.P. The aromatic hydrocarbon receptor, transcription, and endocrine aspects of dioxin action. Vitam. Horm. 2000, 59:241-264.
87. Pavuk M., Michalek J.E., Ketchum N.S. Prostate cancer in US Air Force veterans of the Vietnam war. J. Expo. Sci. Environ. Epidemiol. 2006, 16:184-190.
88. Penna G., Fibbi B., Amuchastegui S., Cossetti C., Aquilano F., Laverny G., Gacci M., Crescioli C., Maggi M., Adorini L. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol. 2009, 182:4056-4064.
89. Powell-Coffman J.A., Bradfield C.A., Wood W.B. Caenorhabditis elegans orthologs of the aryl hydrocarbon receptor and its heterodimerization partner the aryl hydrocarbon receptor nuclear translocator. Proc. Natl. Acad. Sci. USA 1998, 95:2844-2849.
90. Ricke W.A., Ishii K., Ricke E.A., Simko J., Wang Y., Hayward S.W., Cunha G.R. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer 2006, 118:2123-2131.
91. Robert G., Descazeaud A., Nicolaiew N., Terry S., Sirab N., Vacherot F., Maille P., Allory Y., de la Taille A. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009, 69:1774-1780.
92. Rubens R., Dhont M., Vermeulen A. Further studies on Leydig cell function in old age. J. Clin. Endocrinol. Metab. 1974, 39:40-45.
93. Safe S., Qin C., McDougal A. Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer. Expert Opin. Invest. Drugs 1999, 8:1385-1396.
94. Schecter A., Needham L., Pavuk M., Michalek J., Colacino J., Ryan J., Papke O., Birnbaum L. Agent Orange exposure, Vietnam war veterans, and the risk of prostate cancer. Cancer 2009, 115:3369-3371.
95. Seppelt U. Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy. J. Clin. Endocrinol. Metab. 1978, 47:1230-1235.
96. Shibata Y., Ito K., Suzuki K., Nakano K., Fukabori Y., Suzuki R., Kawabe Y., Honma S., Yamanaka H. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000, 42:45-55.
97. Shukla S., Maclennan G.T., Marengo S.R., Resnick M.I., Gupta S. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64:224-239.
98. Simanainen U., Haavisto T., Tuomisto J.T., Paranko J., Toppari J., Tuomisto J., Peterson R.E., Viluksela M. Pattern of male reproductive system effects after in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in three differentially TCDD-sensitive rat lines. Toxicol. Sci. 2004, 80:101-108.
99. Slusarski D.C., Corces V.G., Moon R.T. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997, 390:410-413.
100. Sommer R.J., Sojka K.M., Pollenz R.S., Cooke P.S., Peterson R.E. Ah receptor and ARNT protein and mRNA concentrations in rat prostate: effects of stage of development and 2,3,7, 8-tetrachlorodibenzo-p-dioxin treatment. Toxicol. Appl. Pharmacol. 1999, 155:177-189.
101. Song L., Zhu Y., Han P., Chen N., Lin D., Lai J., Wei Q. A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology 2011, 77:688-692.
102. Steiner G.E., Stix U., Handisurya A., Willheim M., Haitel A., Reithmayr F., Paikl D., Ecker R.C., Hrachowitz K., Kramer G., Lee C., Marberger M. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest. 2003, 83:1131-1146.
103. Sun Q.Z., Guan T.Y., Qi J.G., Cao J.Y., Wu G., Yang N., Cheng Z.Y., Liang J., Wang Q. [Histological characteristics of the prostate in men who receive re-TURP for benign prostatic hyperplasia and their clinical significance]. Zhonghua Nan Ke Xue 2010, 16:118-122.
104. Swanson H.I., Tullis K., Denison M.S. Binding of transformed Ah receptor complex to a dioxin responsive transcriptional enhancer: evidence for two distinct heteromeric DNA-binding forms. Biochemistry 1993, 32:12841-12849.
105. Theobald H.M., Peterson R.E. In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-rho-dioxin: effects on development of the male and female reproductive system of the mouse. Toxicol. Appl. Pharmacol. 1997, 145:124-135.
106. Thomson A.A., Cunha G.R. Prostatic growth and development are regulated by FGF10. Development 1999, 126:3693-3701.
107. Tokizane T., Shiina H., Igawa M., Enokida H., Urakami S., Kawakami T., Ogishima T., Okino S.T., Li L.C., Tanaka Y., Nonomura N., Okuyama A., Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 2005, 11:5793-5801.
108. Tsuchiya Y., Nakajima M., Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J. Biochem. 2003, 133:583-592.
109. Vezina C.M., Allgeier S.H., Moore R.W., Lin T.M., Bemis J.C., Hardin H.A., Gasiewicz T.A., Peterson R.E. Dioxin causes ventral prostate agenesis by disrupting dorsoventral patterning in developing mouse prostate. Toxicol. Sci. 2008, 106:488-496.
110. Vezina C.M., Hardin H.A., Moore R.W., Allgeier S.H., Peterson R.E. 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits fibroblast growth factor 10-induced prostatic bud formation in mouse urogenital sinus. Toxicol. Sci. 2010, 113(1):198-206.
111. Vorderstrasse B.A., Kerkvliet N.I. 2,3,7,8-Tetrachlorodibenzo-p-dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol. Appl. Pharmacol. 2001, 171:117-125.
112. Warot X., Fromental-Ramain C., Fraulob V., Chambon P., Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development 1997, 124:4781-4791.
113. Willey J.J., Stripp B.R., Baggs R.B., Gasiewicz T.A. Aryl hydrocarbon receptor activation in genital tubercle, palate, and other embryonic tissues in 2,3,7, 8-tetrachlorodibenzo-p-dioxin-responsive lacZ mice. Toxicol. Appl. Pharmacol. 1998, 151:33-44.
114. Yamamoto H., Oue N., Sato A., Hasegawa Y., Matsubara A., Yasui W., Kikuchi A. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010, 29:2036-2046.
115. Yamanaka H., Moriguchi T., Masuyama N., Kusakabe M., Hanafusa H., Takada R., Takada S., Nishida E. JNK functions in the non-canonical Wnt pathway to regulate convergent extension movements in vertebrates. EMBO Rep. 2002, 3:69-75.
116. Yu X., Wang Y., Jiang M., Bierie B., Roy-Burman P., Shen M.M., Taketo M.M., Wills M., Matusik R.J. Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 2009, 69:249-262.
117. Zhang T.J., Hoffman B.G., Ruiz de Algara T., Helgason C.D. SAGE reveals expression of Wnt signalling pathway members during mouse prostate development. Gene Expr. Patterns 2006, 6:310-324.